Sign In
|
Register
|
About Los Altos
|
Contact Us
Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast
|
Traffic
Los Altos News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
Los Altos Gas Prices
Ski And Snow Reports
Financial Markets
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Museums
Family Fun
Arts & Culture
Parks
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Art & Culture
Galleries & Dealers
Museums
Associations, Foundations and Organizations
Business & Professional Clubs
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Attractions & Entertainment
Amusement & Water Parks
Bowling, Billiards & Video Games
General Attractions
Golfing
Horseback Riding
Movie Theatres
Theatre
Automotive
Auto Rental
Dealers - New
Dealers - Used
Mobile Home Dealers
Motorcycles
Parts & Supplies
Radio & Alarm Systems
Repair & Service
Tires
Towing
Beauty & Fitness
Barbers
Beauty Salons
Cosmetics
Dance Clubs & Studios
Health Clubs & Gyms
Manicures
Nutrition
Skin Treatment
Yoga
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business & Labor Organizations
Computer & Audio Visual Services
Consultants
Courier, Delivery & Messenger Service
Credit Check & Collection Agencies
Data Processing Service
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Internet Services
Marketing & Advertising Services
Media Services
Notary Services
Photography
Printing & Publishing
Public Relations & Publicity
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Translators & Interpreters
Contractors
Architects
Building Contractors & Consultants
Drywall, Plastering & Insulation
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Housecleaning
Pet Sitting and Day Care
Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Mortgage Lenders
Golf
Government
Post Offices
State Government
Hair Salons
Health and Medicine
Alternative Medicine / Acupuncture
Chiropractors
Counseling
Dentistry
Dermatologists
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Medical Doctors
Medical Equipment & Supplies
Nutrition
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Appliances
Bed & Bath
Building Materials & Hardware
Cleaning Supplies & Services
Contractors
Domestic Services
Doors, Windows & Drapery
Floor Coverings
Furniture
Handyman
Home Improvement Centers
Interior Design & Decorating
Kitchen
Lamps & Lighting
Lawn & Garden
Locksmiths
Lumber
Nurseries & Garden Centers
Painting & Wallcoverings
Pest Control
Plumbing
Pools, Spas & Saunas
Safety & Security
Sewage & Septic Systems
Sprinklers
Insurance
Agents & Brokers
Health
Laser Hair Removal
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Audio & Visual
Building Materials
Computers, Electronics & Telecommunications
Electronic Equipment
Food & Beverage
Industrial Supplies & Services
Machine Shops
Textiles & Apparel
Media
Radio Stations
Television Stations
Meeting & Event Planning
Event Facilities
Exhibit Designers
Meeting Planners
Party Rentals & Entertainment
Miscellaneous
Nightlife
Live Music
Personal Service
Child Care
Dry Cleaning and Laundry
Shoe Repair
Tailors and Alterations
Pets
Pet Grooming
Pet Supplies & Food - Retail
Veterinary Hospitals
Plastic Surgery
Aesthetic Surgeon
Plastic Surgeon
Real Estate
Appraisers
Assisted Living & Elder Care Service
Commercial
Developers
Property Management
Real Estate Agents and Brokers
Residential
Schools
Title Companies
Religion
Relocation
Storage
Restaurants
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Shopping
Accessories
Antiques
Books
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Department Stores
Electronics
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Grocery Stores
Health Food Stores
Home Improvement
Jewelry
Men's Clothing Stores
Pharmacies
Resale Shops
Shoe Stores
Shopping Centers & Malls
Smoke Shops
Sporting Goods
Thrift Stores
Toy Stores
Videos
Women's Clothing Stores
Spas
Day Spas
Resort Spas
Sports & Recreation
Arenas and Venues
Associations & Clubs
Equestrian
Golf Equipment & Supplies
Instruction
Martial Arts
Recreation Facilities
Skateboarding
Technology
Communications
Computer Services & Consultants
Internet Advertising & Services
Semiconductor
Software
Travel & Transportation
Airlines & Airports
Auto Rentals
Bus Lines & Charters
Taxi, Limousine & Shuttle
Tours & Excursions
Travel Agencies
Weddings
Cakes & Caterers
Your Business Here
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in Los Altos
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Morphosys Ag ADR
(NQ:
MOR
)
18.44
+0.14 (+0.77%)
Streaming Delayed Price
Updated: 10:49 AM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Morphosys Ag ADR
< Previous
1
2
3
4
Next >
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
December 12, 2021
MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis - Data presented during poster and oral sessions at the 63rd...
From
MorphoSys AG
Via
AccessWire
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
- RE-MIND2 compared patient outcomes from pivotal L-MIND study with matched patient populations treated with NCCN/ESMO recommended therapies - Results from the retrospective cohort analysis indicate...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
December 11, 2021
From
Incyte
Via
Business Wire
Corporate Calendar 2022
November 29, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 29, 2021 / Corporate Calendar 2022 Dear Madam/Sir, Please note MorphoSys' financial reporting dates 2022 as follows: Publication of Interim Statement /...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
November 11, 2021
- Monjuvi U.S. net product sales of US$ 22.0 million (€ 18.6 million), 22% growth Q-Q - Ten abstracts, including two oral presentations, accepted at upcoming ASH - Pelabresib data for arm 3 of MANIFEST...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
MorphoSys Announces Departure of Roland Wandeler
November 09, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 9, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating...
From
MorphoSys AG
Via
AccessWire
Exposures
Product Safety
MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting
November 04, 2021
Felzartamab has the potential to rapidly and substantially reduce anti-PLA2R antibody titers in patients with anti-PLA2R-positive membranous nephropathy PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
November 04, 2021
- Updates from MANIFEST phase 2 trial in patients with myelofibrosis, including clinical updates on JAK naïve patients treated with pelabresib in combination with ruxolitinib, including translational...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021
November 02, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 2, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to €...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
October 20, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 20, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating...
From
MorphoSys AG
Via
AccessWire
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
October 11, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food...
From
MorphoSys AG
Via
AccessWire
Exposures
Product Safety
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
August 26, 2021
-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL -...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
August 26, 2021
From
Incyte
Via
Business Wire
MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
August 17, 2021
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into...
From
MorphoSys AG
Via
AccessWire
MorphoSys AG Reports Second Quarter and First Half 2021 Results
July 29, 2021
- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities
July 26, 2021
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No 596/2014 PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR)...
From
MorphoSys AG
Via
AccessWire
Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
July 21, 2021
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies,...
From
MorphoSys AG
Via
AccessWire
MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
July 16, 2021
PLANEGG, GERMANY / ACCESSWIRE / July 16, 2021 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) ("MorphoSys") today announced that its Management Board, with the approval of the Supervisory Board, has passed a...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
July 15, 2021
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG...
From
MorphoSys AG
Via
AccessWire
Topics
Earnings
Exposures
Financial
Product Safety
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
July 01, 2021
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino...
From
MorphoSys AG
Via
AccessWire
Exposures
Product Safety
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 25, 2021
From
Incyte
Via
Business Wire
MorphoSys Commences Cash Tender Offer for All Outstanding Shares of Constellation Pharmaceuticals
June 16, 2021
PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of...
From
MorphoSys AG
Via
AccessWire
Exposures
Product Safety
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
June 04, 2021
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
MorphoSys AG to Acquire Constellation Pharmaceuticals and Enter into Strategic Funding Partnership with Royalty Pharma
June 02, 2021
MUNICH, GERMANY and CAMBRIDGE, MA / ACCESSWIRE / June 2, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys"), announces today that it has entered into a definitive agreement with Constellation...
From
MorphoSys AG
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
MorphoSys to Acquire Constellation Pharmaceuticals
June 02, 2021
From
MorphoSys AG
Via
Business Wire
MorphoSys To Participate in UBS Global Healthcare Conference
May 21, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting
May 19, 2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma
May 11, 2021
PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal...
From
MorphoSys AG
Via
AccessWire
Exposures
COVID-19
Product Safety
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
May 11, 2021
From
Incyte
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
Home
|
News
|
Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Events
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.